CG 026806

Drug Profile

CG 026806

Alternative Names: CG026806; CG’806

Latest Information Update: 23 May 2017

Price : $50

At a glance

  • Originator CrystalGenomics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Aurora kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 11 May 2017 Pharmacodynamics data from preclinical studies in Haematological malignancies released by Aptose Biosciences
  • 11 May 2017 Aptose plans a phase I trial for Acute myeloid leukaemia and B-cell malignancies
  • 08 May 2017 Pharmacokinetics and pharmacodynamics data from preclinical studies in Haematological malignancies released by Aptose Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top